指南与共识免疫规划卫生政策与健康促进

欧洲轮状病毒疫苗接种建议综述:呼吁变革

A review of recommendations for rotavirus vaccination in Europe: Arguments for change.
指南 / 共识 · Vaccine · 2018-03-22

该综述梳理欧洲轮状病毒疫苗接种建议现状与阻碍因素,指出仅13国实施全额资助的普遍Mass接种规划,约40%国家无国家层面建议,认为成本和节省效益支持扩大婴儿接种可及性。

要点

  • 欧洲仅13国提供全额资助的轮状病毒普遍Mass接种规划。
  • 约40%欧洲国家目前无国家层面轮状病毒疫苗儿童接种建议。
  • 作者认为成本效益和节省成本效益支持扩大欧洲婴儿轮状病毒疫苗可及性。

核心结论

  • 婴儿轮状病毒普遍Mass接种规划实施超过10年后,现有数据证实其获益和可接受的安全性。
  • 欧洲通过减少接种对象及其未接种兄弟姐妹的医疗资源利用和相关成本(群体保护),可从轮状病毒普遍Mass接种中获得相当收益。
  • 作者认为成本效益和节省成本效益支持为居住在欧洲的婴儿提供更广泛的轮状病毒疫苗可及性。

研究设计与样本

  • 综述概述欧洲轮状病毒疫苗建议现状及阻碍接种的因素,并审视接种获益与风险的证据。

主要发现

  • 欧洲仅13国提供全额资助的轮状病毒普遍Mass接种规划,3国提供部分资助规划,1国为针对高危婴儿的缩减规划提供全额资助。
  • 约40%欧洲国家目前国家政府无儿童轮状病毒疫苗使用建议。
  • 对轮状病毒病直接和间接负担认识不足、轮状病毒疫苗接种可能节省成本(包括对儿童、家庭和社会的相当益处)以及政府/保险公司成本约束,共同导致各国卫生政策不同层面的自满。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: More than 10 years after the authorisation of two rotavirus vaccines of demonstrated efficacy and with a strongly positive benefit-risk profile, uptake in Europe remains low. Only 13 countries in Europe provide a fully-funded rotavirus universal mass vaccination (UMV) programme, three provide a partially-funded programme, and one provides full funding for a reduced programme targeting at-risk infants. Around 40% of countries in Europe currently have no existing recommendations for rotavirus vaccine use in children from the national government. METHODS: We provide an overview of the status of rotavirus vaccine recommendations across Europe and the factors impeding uptake. We consider the evidence for the benefits and risks of vaccination, and argue that cost-effectiveness and cost-saving benefits justify greater access to rotavirus vaccines for infants living in Europe. RESULTS: Lack of awareness of the direct and indirect burden caused by rotavirus disease, potential cost-saving from rotavirus vaccination including considerable benefits to children, families and society, and government/insurer cost constraints all contribute to complacency at different levels of health policy in individual countries. CONCLUSIONS: More than 10 years after their introduction, available data confirm the benefits and acceptable safety profile of infant rotavirus UMV programmes. Europe serves to gain considerably from rotavirus UMV in terms of reductions in healthcare resource utilization and related costs in both vaccinated subjects and their unvaccinated siblings through herd protection.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Poelaert D, Pereira P, Gardner R, et al. A review of recommendations for rotavirus vaccination in Europe: Arguments for change. Vaccine. 2018. PMID: 29576308. doi:10.1016/j.vaccine.2018.02.080

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。